Skip to main content

Table 1 Clinical characteristics of patients with tigecycline-associated coagulation dysfunction events

From: Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database

 

No. of coagulation-dyfunction in tigecycline (%)

No. of other AEs in tigecycline (%)

Gender

 Male

125 (56.05)

520 (40.19)

 Female

69 (30.94)

501 (38.72)

 Missing

29 (13.00)

273 (21.10)

Age

  < 65

69 (30.94)

470 (36.32)

  ≥ 65

98 (43.95)

360 (27.82)

 Missing

56 (25.11)

464 (35.86)

Reporter

 Healthcare workers

130 (58.30)

787 (60.82)

 Non-health care workers

83 (37.22)

457 (35.32)

 Unknown

10 (4.48)

50 (3.86)

Year

 2005–2010

51 (22.87)

420 (32.46)

 2011–2015

71 (31.84)

418 (32.30)

 2016–2020

101 (45.29)

456 (35.24)

Outcome

 Death

45 (20.18)

340 (26.28)

 Life-threatening

28 (12.56)

61 (4.71)

 Disability

0 (0.00)

16 (1.24)

 Hospitalization

35 (15.70)

308 (23.80)

 Other serious

107 (47.98)

405 (31.30)

 Required intervention

1 (0.45)

4 (0.31)

 Missing

7 (3.14)

160 (12.36)

Dosing regimen

 Loading dose

28 (12.56)

86 (6.64)

 Non-loading dose

121 (54.26)

305 (23.57)

 Standard maintenance dosea

111 (49.78)

481 (37.17)

 High maintenance dosec

34 (15.25)

124 (9.58)

Time to event

10 (IQR 6.75–13)

 

Total

223

1294

  1. a Standard maintenance dose means the dose of tigecycline administered at 100 mg/d
  2. b High maintenance dose means the dose of tigecycline administered at 200 mg/d or higher